Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes

    ... elderly patients and those with prior exposure to chemotherapy , radiation, and environmental toxins in the presence of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia

    ... salicylate may be safely combined with conventional chemotherapy regimens which are not associated with significant ototoxicity ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults

    ... hematopoietic growth factors, hypomethylating agents, chemotherapy or transplantation) , progression to acute myeloid ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies

    ... treatment prior to transplantation, including induction chemotherapy (ICT) alone (ICT group; n = 98), AZA alone (AZA group; n = ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes

    ... hematopoietic stem cell disorders that often progress to chemotherapy -resistant secondary acute myeloid leukemia (sAML). We ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Allogeneic stem cell transplantation for myelodysplastic syndromes: critical for cure?

    ... antigen -compatible donor, autologous SCT, or chemotherapy may be good alternatives for those with MDS and with good-risk ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Azacitidine adverse effects in patients with myelodysplastic syndromes

    ... syndromes who are not candidates for high-dose chemotherapy . Considering the mechanism of action of the agent, it is ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Impact on survival of different treatments for myelodysplastic syndromes (MDS).

    ... low-dose Ara-C, antithymocyte globulin (ATG), induction chemotherapy , or allogeneic stem cell transplantation (allo-SCT). For all ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

    ... cytarabine (LDara-C), the most widely used low-dose chemotherapy in patients with higher-risk myelodysplastic syndrome (MDS) ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. The epidemiology of myelodysplastic syndromes.

    ... include advanced age, male gender, previous exposure to chemotherapy or radiation therapy, smoking, or, in rare cases, exposure to ...

    Research Article last updated 07/20/2018 - 5:14pm.